Halozyme Therapeutics, Inc. (HALO) Misses Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.54 -2.25%
EPS Growth %: +30.8%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +30.8%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.31 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
- KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
